期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

腺病毒介导miR-122联合化疗药物ADM对肝癌细胞杀伤作用的研究 被引量：2

Enhanced Inhibitory Effect of Adenovirus-mediated miR-122 Combined with ADM of Growth on Different Hepatocarcinoma Cell Lines
在线阅读 下载PDF
导出
摘要 采用CCK-8比色分析等方法开展腺病毒介导mi R-122联合化疗药物阿霉素(ADM)针对不同人肝癌细胞的杀伤情况的研究。希望通过对比研究,寻找解决化疗药物在临床使用中所出现的疗效低且毒副作用大等难题的方法。研究显示:低浓度的ADM对肝癌细胞的细胞毒作用比较小,但疗效也较差;当ADM浓度增高至80 ng/mL以上,尤其是80 ng/mL的ADM联合20 MOI Ad-mi R122杀伤各种肝肿瘤细胞的能力明显优于单独使用ADM或Ad-mi R122。 To investigate the cytotoxicity effect of adenovirus-mediated miR-122 combined with adriamycin（ADM）on growth of different human hepatocellular carcinoma cell lines by CCK-8 kit.Comparative research can hope to find a solution to the clinical use of chemotherapeutic drugs with low efficacy and high toxicity.The results show that low concentrations of ADM on cytotoxicity of liver cancer cells is relatively small,but the effects are less.When the ADM concentration increases to 80 ng/mL or more,especially 80 ng/mL for ADM combined 20 MOI Ad-miR122 destruction of various liver tumor cells are markedly better than ADM or Ad-miR122 alone.Conclusion： 20 MOI Ad-miR122 combined with 80 ng/mL ADM has enhanced inhibitory effect on growth different human hepatocellular carcionoma cell lines.
作者 徐艳敏 马清华 武佳 李伟 钱程 刘立
机构地区 浙江理工大学生命科学学院
出处 《浙江理工大学学报（自然科学版）》 2010年第6期919-923,共5页 Journal of Zhejiang Sci-Tech University(Natural Sciences)
基金 973计划(2004CB518804) 浙江省"生物医学工程"重中之重学科开放基金(WYX0816)
关键词 ADM Ad-miR122 肝癌细胞株 ADM Ad-miR122 hepatocellular carcinoma cell lines
分类号 Q786 [生物学—分子生物学]
  • 相关文献

参考文献2

二级参考文献28

  • 1Jopling CL, Norman KL, Samow P. Positive and negative modulation of viral and cellular mRNAs by liver-specific microRNA miR-122. Cold Spring Harb Symp Quant Biol, 2006,71:369-376.
  • 2Girard M, Jacquemin E, Munnich A, Lyonnet S, Henrion-Caude A. miR-122, a paradigm for the role of microRNA in the liver. Journal of Hepatology, 2008,48(4): 648-659.
  • 3Moroy T, Marchio A, Etiemble J, Trepo C, Tiollais P, Buendia MA. Rearrangement and enhanced expression of c-myc in hepatocellular carcinoma of hepatitis virus infected woodchucks. Nature, 1986,324(6094):276-279.
  • 4Etiemble J, Moroy T, Jacquemin E, Tiollais P, Buendia MA. Fused transcripts of c-myc and a new cellular locus, hcr in a primary liver cancer. Oncogene, 1989,4(1):51-57.
  • 5Moroy T, Etiemble J, Bougueleret L, Hadchouel M, Tiollais P, Buendia MA. Structure and expression of hcr, a locus rearranged with c-myc in a woodchuck hepatocellular carcinoma. Oncogene, 1989,4(1):59-65.
  • 6Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNA from mouse. Curr Biol, 2002,12(9):735-739.
  • 7Chang J, Provost P, Taylor JM. Resistance of human hepatitis delta virus RNAs to Dicer activity. J Virol, 2003,77: 11910-11917.
  • 8Barrel DP, Chert CZ. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNA. Nat Rev Genet, 2004,5(5):396-400.
  • 9Chang J, Nicolas E, Marks D, Sander C, Lerro A, Buendia MA, Xu C, Mason WS, Moloshok T, Bolt R, Zaret KS, Taylor JM. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol, 2004,1(2): 106-113.
  • 10Lewis BP, Shih IH, Joncs-ghoades MW, Barrel DP, Burge CB. Prediction of mammalian microRNA targets. Cell, 2003, 115(7):787-798.

共引文献25

同被引文献28

  • 1Sugihara H, Ishimoto T, Miyake K, et al. Noncoding RNA ex- pression aberration is associated with cancer progression and is a potential biomarker in esophageal squamous cell carcinoma[J], lnt J Mol Sei, 2015, 16(11): 27824-27834.
  • 20zgar E, Mert U, Isin M, et al. Differential expression of long non-coding RNAs during genotoxic stress-induced apoptosis in HeLa and MCF-7 cells[J]. Clin Exp Med, 2013, 13(2): 119-126.
  • 3Trotter K, Schneider SM, Turner BS. Group appointments in a breast cancer survivorship clinic[J]. J Adv Pract Oneol, 2013, 4 (6): 423-431.
  • 4Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer[J]. N Engl J Med, 2015, 372(2): 134-141.
  • 5Zhang Q, Geng PL, Yin P, et al. Down-regulation of long non-coding RNA TUG1 inhibits osteosarcoma cell proliferation and promotes apoptosis[J]. Asian Pac J Cancer Prey, 2013, 14 (4): 2311-2315.
  • 6Han Y, Liu Y, Gui Y, et al. Long intergenic non-coding RNA TUG1 is over expressed in urothelial carcinoma of the bladder [J]. J Surg Oncol, 2013, 107(5): 555-559.
  • 7Cai H, Xue Y, Wang P, et al. The long noncoding RNA TUGI regulates blood-tumor barrier permeability by targeting miR-144 [J]. Oncotarget, 2015, 6(23): 19759-19779.
  • 8Qiu M, Xu Y, Wang J, et al. A novel lncRNA, LUADT1, pro- motes lung adenocarcinoma proliferation via the epigenetic sup- pression of P27[J]. Cell Death Dis, 2015, 6: Doi: 10.1038/cddis. 2015.203.
  • 9Liao R, Xu Y, Chen M, et al. Molecular mechanism of microR- NA involvement in genesis of myelodysplastic syndrome and its transformation to acute myeloid leukemia[ J ]. Hematology, 2013, 18(4) :191-197. DOI:10. 1179/1607845412Y.0000000053.
  • 10Babashah S, Sadeghizadeh M, Tavirani MR, et al. Aberrant mi- croRNA expression and its implications in the pathogenesis of leu-kemias [ J ]. Cell Oncol (Dordr) , 2012, 35 ( 5 ) : 317-334. DOI : 10.1007/s13402-012-0095-3.

二级引证文献8

浙江理工大学学报（自然科学版）
2010年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部